Nigerian University Says Discovered New Cure for HIV/AIDS
Authorities of Nigeria’s University of Benin (UNIBEN) located in the capital of southern Edo State announced the discovery of a new herbal drug that can cure the dreaded Human Immunodeficiency Virus (HIV) and the Acquired Immune Deficiency Syndrome (AIDS), urging carriers of the disease to give it a try.
Dean of the School of Basic Medical Sciences of UNIBEN Isaiah Ibeh unveiled the herbal drug to reporters, saying it had undergone series of successful tests at the laboratory and by medical experts both in Nigeria and the United States of America, where it passed through more critical tests.
“We are at the threshold of making history, in the sense that we seem to have with us something that will permanently take care of what over time seems to have defied all solutions. We are talking about the latest discovery of an oral drug made from plants extraction in Nigeria for the possible cure of the pandemic, HIV and AIDS virus,” he said, adding that research on the project had commenced in 2010 and culminated in the development of the liquid drug known as Deconction X (DX) or Bioclean 11, for the cure of HIV/AIDS.
“The existing retroviral drugs are intervention drugs for the management of AIDS, but our new discovery is a possible cure,” he said further.
According to Ibeh, the university had tried to look at the herbal drug first, as well as its toxicological analysis and discovered that it has a large safety margin before unveiling it to the public. “This means that if animals or human beings are exposed to it, they will not suffer any serious harm at all from the exposure,” he said.
The Nigerian university also claimed to have obtained a refreshing and revealing result, having done bacteriological analysis on the drug, after which it looked at its effect on the virus. “The drug had performed well on patients with the HIV virus and had shown evidence of total restoration of damaged tissues. The result showed an increase in the body weight of the individuals administered with DX,” Ibeh said.
He said further tests were being conducted to determine the point at which a patient will prove negative after being administered the drug, explaining that this verification became necessary because it is what is used to measure whether an infection was still there or not.
“Preliminary results showed that of the five latest patients orally administered with the drugs within seven months, three of them were siro negative while two were still faintly positive,” he explained, while appealing to government and other relevant bodies to assist the university with relevant equipment to sustain the research.Filed under: Headlines